Free shipping on all orders over $ 500

 About 30 results found for searched term "Raf" (0.009 seconds)

Cat.No.  Name Information
M1669 Regorafenib Regorafenib (BAY 73-4506) is a novel oral multikinase inhibitor of c-KIT, VEGFR2, B-Raf with IC50s of 17, 40 and 69 nM respectively.
M1714 GDC-0879 GDC-0879 is a potent and selective B-Raf kinase inhibitor with an EC50 of 0.75 µM.
M1761 Vemurafenib (PLX4032) Vemurafenib (PLX4032) is the first and effective selective inhibitor of B-Raf, which can inhibit RAFV600E and C-RAF-1 activity with IC50 of 31 nM and 48 nM, respectively. Vemurafenib induces autophagy.
M1774 PLX-4720 PLX-4720 is a selective BRAFV600E inhibitor with the IC50 values of 160 nM and 130 nM for B-Raf and BRK respectively.
M1783 SB590885 SB590885 is a selective small-molecule inhibitor of the B-Raf kinase and Ki values are 0.16 and 1.72 nM for B-Raf and c-Raf respectively.
M1818 ZM 336372 ZM 336372 is a potent, selective ATP-competitive inhibitor of c-Raf in vitro (IC50 = 70 nM for inhibition of human c-Raf).
M1827 Sorafenib Tosylate Sorafenib (BAY 43-9006) Tosylate is an orally active multikinase inhibitor of tyrosine protein kinases VEGFR/PDGFR and RAF/MEK/ERK with IC50 values of 6, 22, 38 nM for Raf-1, wt BRAF and V599E mutant BRAF.
M1855 Dabrafenib Mesylate Dabrafenib (GSK2118436) is a selective, orally bioavailable inhibitor of Mutant B-raf (BRAF) protein kinase with potential antineoplastic activity.
M1863 RAF265 RAF265 is a novel, orally bioavailable dual inhibitor of RAF kinase and VEGFR2.
M1934 Tacrolimus (FK506) Tacrolimus (FK506, FR900506, Fujimycin, Prograf) is a potent, clinically-useful immunosuppressant in the same molecular class as cyclosporin A and rapamycin. *The compound is unstable in solutions, freshly prepared is recommended
M1988 Dabrafenib Dabrafenib (free base) (GSK2118436A) is a V600 mutant BRAF-specific inhibitor.
M25447 PR-104 PR-104 is a novel hypoxia-activated DNA cross-linking agent with marked activity against human tumor xenografts, both as monotherapy and combined with radiotherapy and chemotherapy.
M2045 CEP-32496 CEP-32496 is a potent orally active BRAF inhibitor with IC50 of 14 nM.
M2090 MLN2480 MLN2480 (BIIB-024) is an oral, selective pan-Raf kinase inhibitor.
M2235 TAK-632 TAK-632 is a potent and selective pan-RAF inhibitor.
M2319 AZ628 AZ628 is a potent inhibitor for wild-type CRAF and BRAF V600E with IC50 of 29 nM and 34 nM, respectively.
M2608 Kobe0065 Kobe0065 is a novel and effective small-molecule compound inhibiting Ras–Raf interaction by SBDD, exhibits potent activity to competitively inhibit the binding of H-Ras·GTP to c-Raf-1 RBD with a Ki value of 46 ± 13 μM.
M2743 GW2580 GW2580 is a selective CSF-1R inhibitor for c-FMS with IC50 of 30 nM, 150- to 500-fold selective compared to b-Raf, CDK4, c-KIT, c-SRC, EGFR, ERBB2/4, ERK2, FLT-3, GSK3, ITK, JAK2 etc.
M2744 GW441756 GW441756 is a potent, selective inhibitor of TrkA with IC50 of 2 nM, with very little activity to c-Raf1 and CDK2.
M2745 GW5074 GW5074 is a potent and selective c-Raf inhibitor with IC50 of 9 nM, no effect on the activities of JNK1/2/3, MEK1, MKK6/7, CDK1/2, c-Src, p38 MAP, VEGFR2 or c-Fms is noted.
M2813 LGX818 LGX818 is a highly potent RAF inhibitor with selective anti-proliferative and apoptotic activity in cells expressing B-RAF(V600E) with EC50 of 4 nM.
M2927 PF-04880594 PF-04880594 is a RAF inhibitor for BRAF/BRAFV599E and c-RAF with IC50 of 0.19 nM/0.13 nM and 0.39 nM, >100-fold selectivity over CSNK1, JNK2/3 and p38.
M3026 Sorafenib (BAY 43-9006) Sorafenib (BAY 43-9006) is a multikinase inhibitor of Raf-1, B-Raf and VEGFR-2 with IC50 of 6 nM, 22 nM and 90 nM, respectively.
M3196 CCT239065 CCT239065 is a novel and selective BRAFV600E and LCK inhibitor with IC50 of 13 nM and 6 nM, respectively.
M3898 YK-4-279 YK-4-279 is a potent inhibitor of ETV1 and inhibits both the primary tumor growth and metastasis of fusion positive prostate cancer xenografts.
M4551 Trigonelline-Hydrochloride As an NRF2 inhibitor, fenuelline blocks the expression of NRF2 target genes associated with heme and iron metabolism, synergistic with Erastin and sorafenib to promote iron death in hepatocellular carcinoma cells.
M4644 Dryocrassin-ABBA Dryocrassin ABBA (Dryocrassin) is a natural product of flavonoids extracted from Sophora flavescens, with antiviral and antibacterial activities. Dryocrassin ABBA has antiviral activity against H5N1 avian influenza virus. Dryocrassin ABBA could inhibit coagulase activity of STaphylococcus aureus vWbp. Dryocrassin ABBA can inhibit the immune stimulation of dendritic cells and prolong the survival rate of allografts.
M4869 BAY 87-2243 BAY87-2243 is a potent inhibitor of selective hypoxia-inducible facin-1 (HIF-1). Bay87-2243 induces iron death and necrosis in BRAFV600E melanoma cells by inhibiting the mitochondrial respiratory chain, resulting in ROS accumulation, lipid peroxidation, and GSH deletion.
M5005 Regorafenib Monohydrate Regorafenib is a multi-target inhibitor for VEGFR1, VEGFR2, VEGFR3, PDGFRβ, Kit, RET and Raf-1 with IC50 of 13 nM/4.2 nM/46 nM, 22 nM, 7 nM, 1.5 nM and 2.5 nM, respectively.
M5059 Furafylline Furafylline was a potent, non-competitive inhibitor of high affinity phenacetin O-deethylase activity of microsomal fractions of human liver, a reaction catalysed by P450IA2, with an IC50 value of 0.07 microM.

Contact Us

Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2020 AbMole BioScience. All Rights Reserved.